These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29727755)

  • 1. Are patients' pejorative representations of buprenorphine associated with their level of addiction and of misuse?
    Vanderkam P; Gagey S; Ingrand P; Perault-Pochat MC; Brabant Y; Blanchard C; Tudrej B; Messaadi N; Binder P
    Drug Alcohol Depend; 2018 Jul; 188():10-15. PubMed ID: 29727755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preference for brand-name buprenorphine is related to severity of addiction among outpatients in opioid maintenance treatment.
    Binder P; Messaadi N; Perault-Pochat MC; Gagey S; Brabant Y; Ingrand P
    J Addict Dis; 2016; 35(2):101-8. PubMed ID: 26745033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study.
    Lugoboni F; Zamboni L; Cibin M; Tamburin S;
    Eur Addict Res; 2019; 25(1):10-19. PubMed ID: 30625491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous misuse of buprenorphine: characteristics and extent among patients undergoing drug maintenance therapy.
    Moratti E; Kashanpour H; Lombardelli T; Maisto M
    Clin Drug Investig; 2010; 30 Suppl 1():3-11. PubMed ID: 20450240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients.
    Launonen E; Wallace I; Kotovirta E; Alho H; Simojoki K
    Drug Alcohol Depend; 2016 May; 162():227-35. PubMed ID: 27068849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Misuse of buprenorphine maintenance treatment since introduction of its generic forms: OPPIDUM survey.
    Nordmann S; Frauger E; Pauly V; Orléans V; Pradel V; Mallaret M; Thirion X; Micallef J
    Pharmacoepidemiol Drug Saf; 2012 Feb; 21(2):184-90. PubMed ID: 22109894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.
    Guan Q; Khuu W; Spithoff S; Kiran T; Kahan M; Tadrous M; Martins D; Leece P; Gomes T
    Drug Alcohol Depend; 2017 Aug; 177():315-321. PubMed ID: 28733101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissatisfaction with opioid maintenance treatment partly explains reported side effects of medications.
    Muller AE; Bjørnestad R; Clausen T
    Drug Alcohol Depend; 2018 Jun; 187():22-28. PubMed ID: 29626742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-morbid pain and opioid addiction: long term effect of opioid maintenance on acute pain.
    Wachholtz A; Gonzalez G
    Drug Alcohol Depend; 2014 Dec; 145():143-9. PubMed ID: 25456326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Willingness to receive intravenous buprenorphine treatment in opioid-dependent people refractory to oral opioid maintenance treatment: results from a community-based survey in France.
    Roux P; Rojas Castro D; Ndiaye K; Briand Madrid L; Laporte V; Mora M; Maradan G; Morel S; Spire B; Carrieri P
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):46. PubMed ID: 29096661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Trend in buprenorphine and methadone shopping behavior in France from 2004 to 2014].
    Kernisant M; Delorme J; Kabore JL; Brousse G; Laporte C; Zenut M; Chenaf C; Authier N
    Presse Med; 2016 Dec; 45(12 Pt 1):e369-e375. PubMed ID: 27823911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of opioid maintenance treatments when analgesic treatments are required].
    Laprevote V; Geoffroy PA; Rolland B; Leheup BF; Di Patrizio P; Cottencin O; Schwan R
    Presse Med; 2013; 42(7-8):1085-90. PubMed ID: 23518339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence.
    Fishman MJ; Wu LT; Woody GE
    Am J Psychiatry; 2011 Jul; 168(7):675-9. PubMed ID: 21724673
    [No Abstract]   [Full Text] [Related]  

  • 15. [Investigation of the medical and social situation of patients managed by opiate replacement regimens for over 10 years by their GP].
    Messaadi N; Favre J; Rolland B; Cottencin O; Calafiore M; Stalnikiewicz B; Berkhout C
    Therapie; 2016 Oct; 71(5):439-446. PubMed ID: 27203162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid maintenance therapy in Switzerland: an overview of the Swiss IMPROVE study.
    Besson J; Beck T; Wiesbeck G; Hämmig R; Kuntz A; Abid S; Stohler R
    Swiss Med Wkly; 2014; 144():w13933. PubMed ID: 24706398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-monthly subcutaneous buprenorphine (Sublocade) for opioid use disorder.
    Med Lett Drugs Ther; 2018 Feb; 60(1541):35-37. PubMed ID: 29485976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.